** Shares of Edgewise Therapeutics rise about 17% to $32.28 in premarket trading
** Company says its experimental genetic disorder drug met the main goal in a mid-stage study
** The drug, sevasemten, is being developed to treat Becker Muscular Dystrophy, a rare condition that results in progressive muscle weakness and degeneration
** Sevasemten helped significantly reduce levels of creatine kinase, an enzyme associated with skeletal muscle damage in the study- EWTX
** Up to last close, stock more than doubled YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。